Shanghai Ruiliyuan Biotechnology

Shanghai Ruiliyuan Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative cell and gene therapies for cancer and rare diseases. The company's pipeline is led by HRYZ-T102, an autologous TCR-T cell therapy targeting alpha-fetoprotein (AFP) for the treatment of advanced hepatocellular carcinoma and other AFP-positive solid tumors. Additionally, Ruiliyuan is advancing TX103, a CAR-T therapy targeting B7-H3 for high-grade gliomas, and ST002, a gene therapy candidate for neurofibromatosis type 2. The company focuses on leveraging advanced immune cell engineering to address unmet medical needs in oncology and genetic disorders.